Can antipsychotic dose reduction lead to better functional recovery in first‐episode psychosis? A randomized controlled‐trial of antipsychotic dose reduction. The reduce trial: Study protocol

Antipsychotic medication has been the mainstay of treatment for psychotic illnesses for over 60 years. This has been associated with improvements in positive psychotic symptoms and a reduction in relapse rates. However, there has been little improvement in functional outcomes for people with psychosis. At the same time there is increasing evidence that medications contribute to life shortening metabolic and cardiovascular illnesses. There is also uncertainty as to the role played by antipsychotic medication in brain volume changes.

[1]  C. Correll,et al.  What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia? , 2018, World psychiatry : official journal of the World Psychiatric Association.

[2]  A. Thompson,et al.  Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis , 2016, Early intervention in psychiatry.

[3]  P. McGorry,et al.  Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era , 2016, CNS Drugs.

[4]  M. Olfson,et al.  Premature Mortality Among Adults With Schizophrenia in the United States. , 2015, JAMA psychiatry.

[5]  Costin Tanase,et al.  A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. , 2015, JAMA psychiatry.

[6]  Peter B. Jones,et al.  Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia — An observational 9-year follow-up study , 2014, Schizophrenia Research.

[7]  A. Mackinnon,et al.  Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis , 2014, Psychological Medicine.

[8]  D. Wiersma,et al.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. , 2013, JAMA psychiatry.

[9]  P. McGorry,et al.  Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. , 2013, JAMA psychiatry.

[10]  R. Emsley,et al.  The evidence for illness progression after relapse in schizophrenia , 2013, Schizophrenia Research.

[11]  M. Egan,et al.  Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson’s disease , 2013, Schizophrenia Research.

[12]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[13]  Anvi Vora,et al.  Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. , 2013, The American journal of psychiatry.

[14]  K. Allott,et al.  Utilising Individual Placement and Support to address unemployment and low education rates among individuals with psychotic disorders , 2013, The Australian and New Zealand journal of psychiatry.

[15]  Mario Alvarez-Jimenez,et al.  A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. , 2013, Schizophrenia bulletin.

[16]  R. Emsley,et al.  The nature of relapse in schizophrenia , 2013, BMC Psychiatry.

[17]  A. Comas-Herrera,et al.  Supported employment: cost‐effectiveness across six European sites , 2013, World psychiatry : official journal of the World Psychiatric Association.

[18]  P. McGorry,et al.  ‘Earning and learning’ in those with psychotic disorders: The second Australian national survey of psychosis , 2012, The Australian and New Zealand journal of psychiatry.

[19]  H. Herrman,et al.  A place to live: Housing needs for people with psychotic disorders identified in the second Australian national survey of psychosis , 2012, The Australian and New Zealand journal of psychiatry.

[20]  B. Cornblatt,et al.  Cognitive changes following antidepressant or antipsychotic treatment in adolescents at clinical risk for psychosis , 2012, Schizophrenia Research.

[21]  G. Faber,et al.  The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis , 2012, European Psychiatry.

[22]  Bent Natvig,et al.  A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo , 2011, Journal of clinical psychopharmacology.

[23]  A. Malla,et al.  An examination of patient‐identified goals for treatment in a first‐episode programme in Chennai, India , 2011, Early intervention in psychiatry.

[24]  D. Penn,et al.  Life and treatment goals of individuals hospitalized for first-episode nonaffective psychosis , 2011, Psychiatry Research.

[25]  K. Nuechterlein,et al.  Response to Gordon and Green Letter , 2011 .

[26]  A. Yung,et al.  Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years , 2011, Psychological Medicine.

[27]  Sarah E Hetrick,et al.  Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. , 2011, Schizophrenia bulletin.

[28]  H. Möller,et al.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care , 2011, World psychiatry : official journal of the World Psychiatric Association.

[29]  W. Honer,et al.  Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial , 2010, BMJ : British Medical Journal.

[30]  Wei Deng,et al.  Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. , 2010, Archives of general psychiatry.

[31]  A. David,et al.  Processing speed deficits in schizophrenia: reexamining the evidence. , 2010, The American journal of psychiatry.

[32]  R. Conley,et al.  The cost of relapse and the predictors of relapse in the treatment of schizophrenia , 2010, BMC psychiatry.

[33]  David Castle,et al.  A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. , 2009, The Journal of clinical psychiatry.

[34]  P. McGorry,et al.  Vocational intervention in first-episode psychosis: Individual placement and support v. treatment as usual , 2008, British Journal of Psychiatry.

[35]  Philip D. Harvey,et al.  Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) , 2008, Schizophrenia Research.

[36]  P. McGorry.  Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. , 2007, The American journal of psychiatry.

[37]  D. Wiersma,et al.  Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode Psychosis: Relapse Rates and Functional Outcome , 2007 .

[38]  K. Nuechterlein,et al.  Do Recent-Onset Schizophrenia Patients Experience a “Social Network Crisis”? , 2006, Psychiatry.

[39]  D. Weinberger,et al.  Remission in schizophrenia: proposed criteria and rationale for consensus. , 2005, The American journal of psychiatry.

[40]  M. Knapp,et al.  Relapse in schizophrenia: costs, clinical outcomes and quality of life , 2004, British Journal of Psychiatry.

[41]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[42]  M. Egan,et al.  Comparison of Cognitive Performances During a Placebo Period and an Atypical Antipsychotic Treatment Period in Schizophrenia: Critical Examination of Confounds , 2003, Neuropsychopharmacology.

[43]  P. Appelbaum,et al.  The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. , 2003, The American journal of psychiatry.

[44]  J. Addington,et al.  Medication adherence of individuals with a first episode of psychosis , 2002, Acta psychiatrica Scandinavica.

[45]  G. Bartzokis,et al.  Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. , 2001, The American journal of psychiatry.

[46]  S. Potkin,et al.  Clozapine Enhances Neurocognition and Clinical Symptomatology More Than Standard Neuroleptics , 2001, Journal of clinical psychopharmacology.

[47]  H. Goldman,et al.  Revising axis V for DSM-IV: a review of measures of social functioning. , 1992, The American journal of psychiatry.

[48]  N. Mimica,et al.  Scale for the Assessment of Negative Symptoms (SANS)* , 1989, British Journal of Psychiatry.

[49]  R. Marchbanks.  Choline, acetylcholine and dementia , 1980, Psychological Medicine.

[50]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[51]  R. Dittmann,et al.  Non-adherence to Psychotropic Medication Among Adolescents - A Systematic Review of the Literature. , 2018, Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie.

[52]  S. Schwartz,et al.  Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review. , 2016, American Journal of Orthopsychiatry.

[53]  A. Malhotra,et al.  Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. , 2015, JAMA psychiatry.

[54]  A. Meyer-Lindenberg,et al.  ultimodal meta-analysis of structural and functional brain changes in first pisode psychosis and the effects of antipsychotic medication , 2012 .

[55]  T. Ehmann,et al.  Early Psychosis Services , 2004 .

[56]  L. Mosher,et al.  At issue: predicting drug-free treatment response in acute psychosis from the Soteria project. , 2002, Schizophrenia bulletin.

[57]  R. Liberman,et al.  Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0): Scales, Anchor Points, and Administration Manual , 1993 .

[58]  University of Birmingham Effectiveness of antipsychotics used in first-episode psychosis , 2022 .